About NanoDx, Inc.

NanoDx Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company’s lead product, the NanoDx™ blood test, delivers biologically based results shown to confirm a concussion accurately in less than 90 seconds. The NanoDx™ platform utilizes a patented bio-nanowire technology with the potential for use in a range of applications in point-of-care diagnostics.

In most cases, concussion or mild traumatic brain injury is diagnosed based on a range of subjective, symptom-based tests that are frequently inconclusive. The lack of a rapid, objective diagnostic tool means that a significant percentage of brain injuries go undiagnosed or are diagnosed inaccurately each year. An objective point-of-care system able to diagnose traumatic brain injury in minutes at the time of injury could have significant benefits, potentially leading to faster and more appropriate treatment.


FDA has not yet reviewed this product and it has not been cleared. Currently for research use only.

website icon
Website
employees icon
Employees
industry icon
Industry
Medical Device
location icon
Location
144 Turnpike Rd., Suite 110, Southborough, MA 01772, US
description icon
Founded
2010
description icon
Keywords
Traumatic Brain Injury And Poc Diagnostics

NanoDx, Inc. Alternatives

Industry
Medical Device
Industry
medical device
Industry
medical device
Industry
medical device
Industry
medical device

Frequently Asked Questions about NanoDx, Inc.

Who is the CEO of NanoDx, Inc.?

George J Serafin is the CEO of NanoDx, Inc.. To contact George J Serafin email at [email protected] or [email protected]. Or you may call 973-722-3922

Supercharge your
Prospecting &
Outreach with
ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more